Is Schering's cost squeeze boosting productivity?

Halfway through Schering-Plough's "productivity program"--a.k.a. its $1.5 billion cost-cutting plans--the company's numbers show productivity plateauing, rather than getting better. Report

Suggested Articles

Pfizer's diagnosis-focused launch strategy for Vyndaqel and Vyndamax is paying off with the meds reaching thousands of patients already.

Pfizer terminated a slew of trial cohorts testing Bavencio in combination with its own experimental drugs, as well as one monotherapy trial.

With its Eli Lilly-partnered Olumiant nearing filing in atopic dermatitis, Incyte's other JAK med Jakafi is also looking for a win in that indication.